USPTO 2015–2025 USPTO PatentsView US Corporation

View Point Medical, Inc.

USPTO PatentsView assignee record - 6 granted patents across 2 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

RSS updates for this company

The verdict

According to USPTO PatentsView, View ranks #43,947 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 2 technology areas.

#43,947
of 49,997 US assignees by volume
Top 22%
by Innovation Score (46.0/100)
23.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R43947 · US Corporation #43,947 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 6 grants
  • LOWER-Q #43,947/49,997
  • PHOTO-FINISH Veritas
  • CPC-NARROW A61B · 2 areas
  • INNOV-PAR 46.0/100
  • CLAIMS-DENSE 23.8 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Veritas AG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How View’s 46.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around View

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows View's Innovation Score is 46.0/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for View?

Each dot is one of View’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). View’s own 23.8 claims/patent is ABOVE the 13.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

View vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 5.96.06.066.06.06.1 1015202530 Granted patents (volume) Avg claims / patent Veritas AG - 6, 10.83VeritasVersatile Power, Inc. - 6, 20.5Versatile PowerVertellus Specialties Inc. - 6, 26.83Vertellus Special…Vestel Beyaz Esya Sanayi ve Ticaret Anonim Sirketi - 6, 12.17Vestel Beyaz Esya…Vigilant IP Holdings LLC - 6, 12.67Vigilant IP Holdi…Vinnolit GmbH & Co. KG - 6, 14.67Vinnolit & KGVionx Energy Corporation - 6, 13.5Vionx EnergyVirchow Biotech Pvt. Ltd. - 6, 15Virchow Biotech P…View Point Medical, Inc. - 6, 23.83View Point Medical
View vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where View's grants concentrate

View Point Medical, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2024 (3 grants) versus a trough of 1 in 2021. By volume, View sits between Veritas AG and Virchow Biotech Pvt. Ltd..

View's three-year grant acceleration

View Point Medical, Inc. shows 4 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at View's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows View holds 6 patents at rank #43,949, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near View

By rank, the assignees closest to #43,949 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in View's primary technology class.

View's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 2021202220242025 1
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
View Point Medical, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 1 16.7%
2022 1 16.7%
2024 3 50.0%
2025partial year 1 16.7%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

View Point Medical, Inc.'s patent record in context - here's where to go next.

  • View Point Medical, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
  • Ranked #43,947 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare View Point Medical, Inc. against Veritas AG, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 46.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.